Gilead Announces Executive Promotions
January 28 2015 - 4:30PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the
promotion of Andrew Cheng, MD, PhD to Executive Vice President, HIV
Therapeutics and Development Operations, and Taiyin Yang, PhD, to
the role of Executive Vice President, Pharmaceutical Development
and Manufacturing. Dr. Cheng and Dr. Yang will both join Gilead’s
senior leadership committee.
Dr. Cheng joined Gilead in 1999. He has led clinical development
activities for the company’s development-stage programs in
HIV/AIDS. In 2009, he was appointed Senior Vice President, HIV
Therapeutics and Development Operations, assuming additional
responsibility for biometrics, clinical operations, clinical
pharmacology, drug safety and public health, project management and
regulatory affairs. Dr. Cheng reports to Norbert Bischofberger,
PhD, Executive Vice President, Research and Development and Chief
Scientific Officer. Prior to joining Gilead, Dr. Cheng trained in
internal medicine at the University of California, Los Angeles. He
received his medical degree and PhD in Cellular and Molecular
Biology from Columbia University and his undergraduate degree from
the Johns Hopkins University.
Dr. Yang joined Gilead in 1993 and was promoted to Senior Vice
President in 2005. In her newly expanded role, Dr. Yang is
responsible for managing pharmaceutical development, analytical
operations, laboratory information, quality assurance and
manufacturing of both clinical and commercial drug substance and
drug product. She reports to Dr. Bischofberger and to John
Milligan, PhD, President and Chief Operating Officer. Prior to
joining Gilead, Dr. Yang was Director of Analytical Chemistry at
Syntex. Dr. Yang received her bachelor’s degree in Chemistry from
National Taiwan University and her PhD in Organic Chemistry from
the University of Southern California.
“Andrew and Taiyin have both demonstrated leadership in bringing
groups together to help expedite the development and manufacturing
of products – ultimately allowing the company to reach patients in
need more quickly,” commented Dr. Bischofberger. “They are experts
in their respective fields and have helped build teams that are
efficient and highly productive. These promotions recognize their
achievements and dedication to bringing innovative new therapies to
patients around the world.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
For more information on Gilead Sciences, please
visit the company’s website at www.Gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.Patrick O’Brien, 650-522-1936
(Investors)Amy Flood, 650-522-5643 (Media)
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024